Phase 2 & Phase 3 Trials • NEJM

Retatrutide: What the Research Actually Shows

📄 7 PubMed citations🧪 Phase 3 trial

Last updated: October 3, 2026

Retatrutide (LY3437943) produced a mean −25.0% body weight change on 12 mg at 80 weeks in Eli Lilly's Phase 3 TRIUMPH-1 obesity trial, per the peer-reviewed NEJM paper (PMID 42814954, intention-to-treat estimand). A higher 28.3% figure is company-reported (Lilly's efficacy estimand) and does not appear in the peer-reviewed paper's abstract; source: Lilly's topline release (May 21, 2026). The earlier Phase 2 trial (NEJM 2023) reported 24.2% at 48 weeks. It works by simultaneously activating three metabolic receptors: GLP-1, GIP, and glucagon.

Where to buy · affiliate link
Retatrutide 10 mglisted as GLP-3 RT at Veratis$80

Code HIGHPEPTIDES takes 15% off at checkout: $68

Third-party COA on every lotIn stockShips in the lower 48, $15 standard
Buy retatrutide at Veratis →

Affiliate link: HighPeptides earns a commission on orders. Research use only. Educational content, not medical advice.

25.0%
Mean Weight Loss
(12mg, 80 weeks, TRIUMPH-1, ITT)
2339
Randomized
(TRIUMPH-1)
3
Receptor Targets
(GIP + GLP-1 + Glucagon)

Build your own printable peptide tracker

A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →
✅ Phase 3 — reported

Phase 3 TRIUMPH-1 has reported — −25.0% mean weight change on 12 mg

In Eli Lilly's Phase 3 TRIUMPH-1 obesity trial (80 weeks), the peer-reviewed NEJM paper (PMID 42814954) reports a mean −25.0% body weight change on 12 mg under intention-to-treat, versus −3.9% with placebo. The original Phase 2 trial (Jastreboff et al., NEJM 2023, PMID 37366315) reported 24.2% on 12 mg at 48 weeks. Retatrutide remains investigational and is not yet FDA-approved.

A Triple Receptor Agonist

Retatrutide (LY3437943) simultaneously activates three metabolic receptors, a combination no approved drug achieves. Here is what each target is thought to do.

🔵

GLP-1 Receptor

Thought to reduce appetite, slow gastric emptying, and enhance insulin secretion in response to meals. This is the same target as semaglutide (Ozempic/Wegovy).

🟢

GIP Receptor

Thought to support insulin secretion and fat metabolism. This is the same second target used by tirzepatide (Mounjaro/Zepbound).

★ The Third Target 🟣

Glucagon Receptor

The third target. Glucagon-receptor activation is thought to raise energy expenditure and liver fat metabolism. This is a proposed mechanism, not a result measured in the retatrutide trials cited here.

Weight Loss by Dose

Average percent body weight lost across all dose groups, measured at 24 and 48 weeks. Bars animate when you scroll to this section.

24-Week Results
Placebo −1.6%
1mg dose −7.2%
4mg dose −12.9%
8mg dose −17.3%
12mg dose −17.5%
48-Week Results
Placebo −2.1%
1mg dose −8.7%
4mg dose
−17.1%
8mg dose −22.8%
12mg dose ★ Maximum
−24.2%

Who Actually Loses Weight?

Percentage of participants achieving meaningful weight loss thresholds at 48 weeks. The higher the dose, the more consistent the results.

12mg · Peak Dose
100%
≥5% weight loss
93%
≥10% weight loss
83%
≥15% weight loss
8mg Dose
100%
≥5% weight loss
91%
≥10% weight loss
75%
≥15% weight loss
4mg Dose
92%
≥5% weight loss
75%
≥10% weight loss
60%
≥15% weight loss
Placebo
27%
≥5% weight loss
9%
≥10% weight loss
2%
≥15% weight loss

How Does It Compare?

Retatrutide vs the two leading approved GLP-1 medications. Figures are each drug's highest-dose mean change from its own placebo-controlled trial (treatment-regimen / intention-to-treat estimand) — cross-trial numbers, see the note below.

Tirzepatide
Mounjaro / Zepbound • Eli Lilly
Mechanism Dual agonist
(GIP + GLP-1)
Mean Weight Change −20.9%
(15 mg, 72 weeks, SURMOUNT-1; Jastreboff et al., NEJM 2022, PMID 35658024)
FDA Status ✓ Approved (Zepbound)
Injection Weekly ✓
Availability Available now
Semaglutide
Ozempic / Wegovy • Novo Nordisk
Mechanism Single agonist
(GLP-1 only)
Mean Weight Change −14.9%
(2.4 mg, 68 weeks, STEP 1; Wilding et al., NEJM 2021, PMID 33567185)
FDA Status ✓ Approved (Wegovy)
Injection Weekly ✓
Availability Available now
⚠️
Important caveat: These are cross-trial comparisons, not head-to-head. Different study designs, patient populations, dose escalation protocols, and trial durations make direct comparison inherently imprecise. No head-to-head trial of retatrutide against tirzepatide or semaglutide has been published, and the three trials ran for different lengths (80, 72 and 68 weeks).

Side Effects Breakdown

What the published trial abstracts report about safety. Per-event rates by dose are in the full papers and are not reproduced here.

Gastrointestinal events
The most common adverse events in both the phase 2 trial (PMID 37366315) and phase 3 TRIUMPH-1 (PMID 42814954).
Dose-related, mostly mild to moderate
In phase 2, GI events increased with dose and were mostly mild to moderate in severity (PMID 37366315).
Heart rate increase
Phase 2 reported dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter (PMID 37366315).

Titration Matters

Starting at 2mg and slowly titrating up to higher doses partially mitigated GI side effects compared to starting directly at 4mg in the phase 2 trial (PMID 37366315).

What the Abstracts Don't Report

Neither trial abstract gives per-event adverse-event percentages or a discontinuation rate due to adverse events, so this page does not state them. See the full NEJM papers for those figures.

Dose and Tolerability

Because GI events were dose-related in phase 2, higher doses carried more of them. Long-term safety beyond the trial periods has not been established.

Trial Details

The trial details below are from the Phase 2 NEJM publication; other figures on this page are cited where they appear. Full citation below.

Phase 2 Randomized Controlled Trial

Retatrutide (LY3437943) for Obesity — Full Study Record

Trial ID NCT04881760
Published New England Journal of Medicine, August 10, 2023
Authors Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML, et al.
Funded By Eli Lilly and Company
Duration 48 weeks of treatment
Participants 338 adults (51.8% men)
Population Adults with BMI ≥30, or BMI 27–29.9 with at least one weight-related condition (e.g., hypertension, dyslipidemia, obstructive sleep apnea)
Design Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study
Primary Endpoint Percent change in body weight from baseline to 24 weeks

Phase 3 TRIUMPH: Results & What's Next

Eli Lilly's Phase 3 TRIUMPH-1 obesity trial has now been published in NEJM. Here is what the paper reports.

Phase 3 Weight Loss Data: Reported

Eli Lilly's Phase 3 TRIUMPH-1 obesity trial (80 weeks, 2339 participants randomized) reported a mean body weight change of −25.0% on 12 mg, −23.7% on 9 mg and −17.6% on 4 mg, versus −3.9% with placebo, under the intention-to-treat estimand (NEJM, PMID 42814954). Lilly's topline release gave a higher, company-reported 28.3% for 12 mg under Lilly's efficacy estimand; that figure does not appear in the peer-reviewed paper's abstract. For context, the Phase 2 trial reported 24.2% on 12 mg at 48 weeks (Jastreboff et al., NEJM 2023, PMID 37366315). The TRIUMPH-1 paper reports WOMAC knee-pain score changes of up to −4.1 points (ITT; −2.5 with placebo) in participants with knee osteoarthritis, and apnea-hypopnea index changes of up to −34.3 events/hour (9 mg, ITT; vs −9.6 with placebo) in participants with obstructive sleep apnea.

What the TRIUMPH Program Covers

TRIUMPH-1 enrolled adults with obesity without diabetes, with prespecified subgroups of 574 participants with knee osteoarthritis and 243 with obstructive sleep apnea (PMID 42814954). Results from Lilly's other TRIUMPH trials are not covered on this page.

Retatrutide remains investigational and is not FDA-approved.

Who Researches Retatrutide?

This Research Is Commonly Explored By People Who...

  • Are interested in the next generation of multi-receptor agonists (GLP-1/GIP/glucagon triple agonist)
  • Want to understand Phase 2 data showing up to 24% weight loss at 48 weeks
  • Have followed GLP-1 research and want to track emerging therapies in the pipeline
  • Are curious about glucagon receptor activation and its role in energy expenditure
  • Want to compare retatrutide's early data against approved options like semaglutide and tirzepatide

This Research May Not Be Relevant If...

  • You want something available now. Retatrutide has reported Phase 3 results but is not yet FDA approved
  • You prefer established safety profiles. Long-term data is still being collected
  • You need a treatment plan today. Discuss approved options with your healthcare provider first
📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.


Get the Guide: $19 (normally $29) →
The GLP-1 Owner’s Manual ($19)

What the Data Actually Tells Us

Separating confirmed Phase 2 and Phase 3 findings from what still needs to be established before FDA review.

✅ What We Know
  • Phase 3 TRIUMPH-1 (80 weeks) reported a mean −25.0% body weight change on 12 mg vs −3.9% with placebo (ITT, NEJM, PMID 42814954); Phase 2 reported 24.2% on 12 mg at 48 weeks (PMID 37366315)
  • In Phase 2, 100% of participants on the 8mg and 12mg doses lost at least 5% of body weight at 48 weeks (PMID 37366315)
  • Gastrointestinal events were the most common adverse events; in Phase 2 they were dose-related, mostly mild to moderate, and partially mitigated by a lower 2 mg starting dose (PMID 37366315)
  • In Phase 2, mean weight loss on 12 mg increased from 17.5% at 24 weeks to 24.2% at 48 weeks (PMID 37366315)
⚠️ What We Don't Know Yet
  • Results from the other Phase 3 TRIUMPH trials are not covered on this page
  • Long-term safety beyond the 80-week TRIUMPH-1 treatment period has not yet been established in published data
  • No published head-to-head trials against tirzepatide or semaglutide exist. Cross-trial comparisons have real limitations
  • FDA approval timeline remains uncertain; retatrutide is still investigational
  • Real-world effectiveness may differ from the highly controlled clinical trial setting (adherence, diet, comorbidities)

Mental Clarity, Cognition & Inflammation

Can retatrutide affect focus or inflammatory "stiffness"? No retatrutide trial has tested this. Here is the receptor-level mechanism — and exactly where the evidence stops.

Cognition. In a randomized phase 2b trial in 204 people with mild to moderate Alzheimer's disease, liraglutide showed no significant difference from placebo in cerebral glucose metabolism (the primary endpoint); one secondary executive-function score (ADAS-Exec) performed better with liraglutide at an unadjusted P value, while two other secondary measures (daily activities, dementia rating) showed no significant difference — an exploratory signal, not evidence that liraglutide slows decline (Edison et al., Nat Med 2026, PMID 41326666), and in a randomized trial, exenatide showed better off-medication motor scores than placebo (adjusted between-group difference) in Parkinson's disease (Athauda et al., Lancet 2017, PMID 28781108). Retatrutide also activates GIP and glucagon receptors; whether that adds any cognitive effect has not been tested in a retatrutide trial.

Inflammation. In preclinical models, dual GLP-1 / GIP receptor agonists reduced brain inflammation and protected synaptic numbers and synaptic activity (Hölscher review, Neuropharmacology 2018, PMID 29402504). Systemically, any anti-inflammatory effect could partly reflect fat loss itself, since adipose tissue releases inflammatory signaling molecules such as IL-6 and TNF-α; retatrutide produced large reductions in body weight — a mean 24.2% of total body weight at 48 weeks on the 12 mg dose in the Phase 2 obesity trial (Jastreboff et al., NEJM 2023, PMID 37366315). No retatrutide trial cited here measured inflammatory markers.

What we don't know. No retatrutide-specific trial has yet powered a cognition score or an inflammatory marker (CRP, IL-6) as a primary endpoint. The cognition and neuroinflammation findings above are GLP-1 class effects and preclinical mechanism — mixed supporting evidence (the liraglutide trial missed its primary endpoint), not retatrutide-specific proof.

→ Full deep-dive: Retatrutide Beyond Weight Loss

Essential Supplies

Everything you need for peptide preparation and administration

💧 Bacteriostatic Water For reconstitution 💉 Insulin Syringes 29g for precise dosing 🧴 Alcohol Swabs Sterilize before injection ⚖️ Body Composition Scale Track lean mass vs. fat changes during weight loss. 🥗 Digital Food Scale Gram-accurate portions for protein-first eating during appetite suppression. 🩸 Blood Glucose Meter For baseline and fasting glucose tracking. 🗑️ Sharps Container FDA-cleared sharps disposal — never use household trash.

Affiliate links support HighPeptides at no extra cost.

What to Expect: A Patient Timeline

Based on the retatrutide Phase 2 trial (NEJM 2023, NCT04881760, n=338, PMID 37366315) at the highest dose (12 mg/week), plus the Phase 3 TRIUMPH-1 result where noted. Lower doses produced smaller effects, with the dose response flattening between 8 mg and 12 mg. Individual results vary significantly.

Week 1–2

Triple Receptor Activation & Dose Escalation

GIP + GLP-1 + Glucagon Most common AEs: GI Dose: 2 mg/wk start

Retatrutide simultaneously activates GIP, GLP-1, and glucagon receptors — a triple mechanism that distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GIP + GLP-1). GLP-1 activity is thought to suppress appetite; the GIP and glucagon components are thought to add metabolic effects, which has not been measured directly in these trials. In Phase 2 the 12 mg group started at 2 mg; GI events were the most common adverse events, were dose-related, and were partially mitigated by the lower starting dose (PMID 37366315).

Month 1

Early Weight Loss

Early loss begins

The glucagon receptor component of retatrutide is thought to raise energy expenditure, a proposed mechanism rather than a measured trial result. The trial abstracts do not report month-1 weight change or food intake.

Week 24

Week-24 Weight Loss

~17.5% loss by wk 24

By week 24, the 12 mg group in the Phase 2 trial showed a mean 17.5% body weight loss, versus 1.6% with placebo (PMID 37366315). Week 24 was the trial's primary endpoint.

Week 48+

Continued Weight Loss to 48 and 80 Weeks

24.2% at 48 wks (Phase 2) 25.0% at 80 wks (TRIUMPH-1, ITT)

The Phase 2 trial showed 24.2% average body weight loss at 48 weeks in the highest-dose group (12 mg), versus 2.1% with placebo (PMID 37366315). In the separate, larger Phase 3 TRIUMPH-1 trial, the 12 mg group's mean body weight change at 80 weeks was −25.0% versus −3.9% with placebo under intention-to-treat (NEJM, PMID 42814954).

⚖️

Sleep Apnea Data — and Nausea Around Bedtime

The weight loss driven by GLP-1/GIP/glucagon tri-agonists like retatrutide may also benefit obesity-related sleep apnea. In TRIUMPH-1, participants with obstructive sleep apnea had apnea-hypopnea index (AHI) changes of up to −34.3 events/hour (9 mg, ITT) vs −9.6 with placebo (NEJM, PMID 42814954).

GI effects such as nausea were the most common adverse events in the trials and could plausibly interfere with sleep; how dose timing affects sleep has not been studied in retatrutide trials.

→ Sleep Optimization for GLP-1 Users
Affiliate Vendor

Retatrutide (Research Peptide)

The triple-agonist (GLP-1/GIP/glucagon) with reported Phase 3 TRIUMPH-1 results. Research peptides are not FDA-approved for human use. Review each product’s certificate of analysis before buying.

Browse Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost.

Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Retatrutide is an investigational drug not yet approved by the FDA for any indication. Always consult with a qualified healthcare provider before starting any medication or treatment protocol. Data sourced from published peer-reviewed research (NEJM 2023, NCT04881760; NEJM 2026, NCT05929066) unless otherwise cited.

📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.